Head-to-head evidence
Divozilimab vs Ocrelizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Divozilimab
Developed by Biocad
NCT06987851 · Phase 3 · completed
This was an open-label, single-group extension study without a comparator, enrolling 44 participants who continued from the prior BCD-132-4/MIRANTIBUS study after earlier BCD-132 treatment. Its primary endpoint was the clinical measure of annualized relapse rate at 48 and 96 weeks, but the result was not reported.
Ocrelizumab
Marketed by Roche
NCT00676715 · Phase 2 · completed
Randomized, double-blind phase 2 in relapsing-remitting multiple sclerosis (220 participants). Both ocrelizumab doses reduced gadolinium-enhancing brain lesions decisively versus placebo (p<0.0001); the endpoint is an MRI biomarker rather than a clinical relapse or disability outcome, which is why the grade is moderate despite the clear result.
Next expected readout: October 2026 · NCT03523858 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divozilimab's landscape · Ocrelizumab's landscape